We are going to focus our scientific interest on patients with early-onset cardiovascular diseases, hematological patients with suspected but not confirmed MDS, and breast cancer patients with BRCA1/2 germline mutations who have received chemotherapy and/or PARP inhibitor therapy. Here, PARP1 is linked to myelodysplastic syndrome.